Transforming Surgical Eye Care with Robotics: Our Series B Investment in ForSight
Forsight’s $125M Series B is one of the largest surgical robotics rounds to date and will support the company’s continued development, scale-up, and clinical testing of the ORYOM platform
Vision impairment is one of the most pervasive disabilities on earth. It doesn’t have to be. Of the more than two billion people around the world who suffer from vision impairment or blindness, half of those cases could be successfully treated — if not prevented entirely. But there is a glaring gap between the number of people in need of sight-restoring surgery and the number of skilled ophthalmic surgeons available to perform it. This shortage is only projected to increase as fewer ophthalmic surgeons enter the field each year despite a continuous surge in demand for care. This is a clear example of an urgent, global problem that can only be solved by leveraging cutting-edge technology that allows us to do more with less. We can’t magically produce more ophthalmic surgeons around the world — but with robotics, we can effectively expand their reach. ForSight Robotics is delivering on this vision with a surgical robotics system to equip medical professionals with the tools and support to perform life-changing, sight-restoring cataract surgery. As one of the most commonly performed surgical procedures in the world (second only to blood draws in volume) even incremental improvement in cataract surgery could unlock meaningful improvement for millions of patients. But ForSight isn’t aiming for incremental gains; it’s building something fundamentally new. The company’s ORYOM™platform enables sub-micron precision and unlocks new levels of consistency and safety in cataract surgery. Eclipse is proud to be leading the company’s $125M Series B. Renowned physician Dr. Frederic Moll, widely known as the “father of surgical robotics,” also participated in the round along with Reiya Ventures and other existing investors. With the latest funding — which is one of the largest surgical robotics rounds to date — the company will continue development, scale-up, and clinical testing of ORYOM.
